Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03250117 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
A Phase 1 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03250117 is a Phase 1 study that was terminated before completion, run by Titan Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT03250117, a Phase 1 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeura™ implant technology where the implant is inserted under the skin. This study will measure how much ropinirole is released in the blood during 12 weeks of ropinirole implant treatment, and evaluate the side effects of this new formulation.
Interventions
- DRUG Ropinirole oral product
- DRUG Ropinirole Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03250117
The ClinicalTrials.gov registry entry for NCT03250117 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ropinirole oral product is the first listed.
NCT03250117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03250117 about?
NCT03250117 is a clinical study titled "Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole". Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeura™ implant technology where the implant is inserted under the skin. This study will measure how much ropinirole is released in the bl...
What is the current status of trial NCT03250117?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-10-10. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT03250117?
The interventions under investigation include: Ropinirole oral product (DRUG), Ropinirole Implant (DRUG).
Who is sponsoring clinical trial NCT03250117?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.